Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-25
2011-01-25
Romeo, David S (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S009100, C514S017100, C424S422000, C530S395000
Reexamination Certificate
active
07875591
ABSTRACT:
A device comprising a scaffold coated with a protein having at least 83% identity to the amino acid sequence of the core protein of domain I of a mammalian perlecan, wherein at least one glycosaminoglycan is attached to the protein is described. The device may be used in vitro or in vivo to induce replication and/or differentiation of connective tissue cells and to repair tissue.
REFERENCES:
patent: 5206023 (1993-04-01), Hunziker
patent: 5661127 (1997-08-01), Bhatnagar et al.
patent: 5842477 (1998-12-01), Naughton et al.
patent: 5876730 (1999-03-01), Brigstock et al.
patent: 6514514 (2003-02-01), Atkinson et al.
patent: WO 98/08381 (1998-03-01), None
patent: WO 99/06054 (1999-02-01), None
Notice of Allowance dated Jun. 22, 2010 for U.S. Appl. No. 12/398,534.
Arikawa-Hirasawa, Eri et al., “Perlecan is essential for cartilage and cephalic development,” Nature Genetics; Nov. 1999; vol. 23; pp. 354-358.
Atkinson, Brent et al., “Combination of Osteoinductive Bone Proteins Differentiates Mesenchymal C3H/10T1/2 Cells Specifically to the Cartilage Lineage,”Journal of Cellular Bichemistry, No. 65, pp. 325-339 (1997).
Aviezer, David et al., “Perlecan, Basal Lamina Proteoglycan, Promotes Basic Fibroblast Growth Factor-Receptor Binding, Mitogenesis, and Angiogenesis,”Cell; Dec. 18, 1994; 79:1005-1013.
Brown, Judith et al., “The C-terminal domain V of perlecan promotes β1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans,”Eur. J. Biochem., 1997; 250:39-46.
Chintala, Shravan, “Basic Fibroblast Growth Factor Binds to Heparan Sulfate in the Extracellular Matrix of Rat Growth Plate Chondrocytes,”Archives of Biochemistry and Biophysics; Apr. 1994; 310(1):180-186.
Cohen, Isabelle R. et al., “Structural characterization of the complete human perlecan gene and its promoter,”Proc. Natl. Acad. Sci. USA; Nov. 1993; 90:10404-10408.
Costell, Mercedes et al., “Structural characterization of recombinant domain II of the basement membrane proteoglycan perlecan,”FEBS Letters; 1996; 396:127-131.
Costell, Mercedes et al., “Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides,”Eur. J. Biochem.; 1997; 243:115-121.
Costell, M. et al., “Perlecan maintains the integrity of cartilage and some basement membranes,”J. Cell Biol.; 1999; 147:1109-1122.
Couchman, John R. et al., “Perlecan and Basement Membrane-Chondroitin Sulfate Proteoglycan (Bamacan) Are Two Basement Membrane Chondroitin/Dermatan Sulfate Proteoglycans in the Engelbreth-Holm-Swarm Tumor Matrix,”The Journal of Biological Chemistry, 1996; 271(16):9595-9602.
Cuevas, Pedro et al., “Basic Fibroblast Growth Factor (FGF) Promotes Cartilage Repair In Vivo,”Biochemical and Biophysical Research Communications; Oct. 31, 1988; 156(2):611-618.
French, M. M. et al., “Expression of the Heparan Sulfate Proteoglycan, Perlecan, During Mouse Embryogenesis and Perlecan Chondrogenic Activity In Vitro,”The Journal of Cell Biology; May 31, 1999; 145(5):1103-1115.
Friedrich, Martin V. K. et al., “Structural Basis of Glysosaminoglycan Modification and of Heterotypic Interactions of Perlecan Domain V,”J. Micro. Biol.; 1999; 294:259-270.
Geberhiwot, Tarekegn et al., “Chain specificity assignment of monoclonal antibodies to human laminins by using recombinant laminin β1 and γ1 chains,”Matrix Biology; 2000; 19:163-167.
Graham, Lloyd D. et al., “Expression of Human Perlecan Domain I as a Recombinant Heparan Sulfate Proteoglycan with 20-kDa Glycosaminoglycan Chains,”Biochemical and Biophysical Research Communications; 1999; 256:542-548.
Groffen, Alexander J.A. et al., “Expression and characterization of human perlecan domains I and II synthesized by baculovirus-infected insect cells,”Eur. J. Biochem.; 1996; 241:827-834.
Iozzo, Renato V. et al., “The biology of perlecan: the multifaceted heparin sulphate proteoglycan of basement membranes and pericellular matrices,”Biochem. J.; 1994; 302:625-639.
Iwamoto, M. et al., “Actions of Hedgehog Proteins on Skeletal Cells,”Crit, Rev. Oral Biol. Med., 1999; 10(4):477-486.
Kawaguchi, Hiroshi et al., “Stimulation of Fracture Repair by Recombinant Human Basic Fibroblast Growth Factor in Normal and Streptozotocin-Diabetic Rats,”Endocrinology, 1994; 135(2):774-781.
Ko, Cheol W. et al, “Cyclic AMP regulates basement membrane heparin sulfate proteoglycan, perlecan, metabolism in rat glomerular epithelial cells,”Molecular and Cellular Biochemistry, 1996; 162:65-73.
Kokenyesi, Robert et al., “Formation of Heparan Sulfate or Chondroitin/Dermatan Sulfate on Recombinant Domain I of Mouse Perlecan Expressed in Chinese Hamster Ovary Cells,”Biochemical and Biophysical Research Communications, Jun. 6, 1995; 211(1):262-267.
Lanske, et al., “Ablation of the PTHrP Gene of the PTH/PTHrP Receptor Gene Leads to Distinct Abnormalities in Bone Development,”The Journal of Clinical Investigation; Aug. 1999; 104(4):399-407.
Matsunaga, Shunji et al., “Temporal and spatial expressions of transforming growth factor-βs and their receptors in epiphyseal growth plate,”International Journal of Oncology, No. 14, 1999, pp. 1063-1067.
Mello, Marie Alice et al., “High Density Micromass Cultures of Embryonic Limb Bud Mesenchymal Cells, an in Vitro Model of Endochondrial Skeletal Development,”In Vitro Cell Dev, Biol.-Animal, No. 35, May 1999, pp. 262-269.
Miyakoshi, Naohisa et al., “Effects of intraarticular administration of basic fibroblast growth factor with hyaluronic acid osteochondral defects of the knee in rabbits,”Arch. Orthop. Trauma Surg., 2005, vol. 125, pp. 683-692.
Mongiat, Maurizio et al., “The Protein Core of the Proteoglycan Perlecan Binds Specifically to Fibroblast Growth Factor-7,”The Journal of Biological Chemistry; Mar. 10, 2000; 275(10):7095-7100.
Mongiat, Maurizio et al., “Fibroblast Growth Factor-binding Protein Is a Novel Partner for Perlecan Protein Core,”The Journal of Biological Chemistry; 2001; 276(13):10263-10271.
Murdoch, Alan D. et al., “Primary Structure of the Human Heparan Sulfate Proteoglycan from Basement Membrane (HSPG2/Perlecan),”The Journal of Biological Chemistry; Apr. 25, 1992; 267(12):8544-8557.
Nakajima, Hideto et al., “Characterization of the cells in the repair tissue of full-thickness articular cartilage defects,”Histochem. Cell Biol., 1998; 109:331-328.
Noonan, Douglas et al., “The Complete Sequence of Perlecan, a Basement Membrane Heparan Sulfate Proteoglycan, Reveals Extensive Similarity with Laminin A. Chain, Low Density Lipoprotein-Receptor, and the Neural Cell Adhesion Molecule,”The Journal of Biological Chemistry; Dec. 5, 1991; 266(34):22939-22947.
Ornitz, David M., “FGFs, heparin sulfate and FGFRs: complex interaction essential for development,”BioEssays; 2000; 22:108-112.
Perrimon, Norbert et al., “Specificities of heparin sulphate proteoglycans in developmental processes,”Nature; Apr. 13, 2000; 404:725-728.
Reddi, A. Hari, “Cartilage Morphogenesis: Role of Bone and Cartilage Morphogenetic Proteins, Homeobox Genes and Extracellular Matrix,”Matrix Biology; 1994; 14:599-606.
Rescan, Pierre-Yves et al., “Distribution and Origin of the Basement Membrane Component Perlecan in Rat Liver and Primary Hepatocyte Culture,”American Journal of Pathology; Jan. 1993, 142(1):199-208.
San Antonio, James D. et al., “Regulation of Chondrogenesis by Heparan Sulfate and Structurally Related Glycosaminoglycans,”Develomental Biology; 1987; 123:17-24.
Sasaki, Takako et al., “Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin,”
Carson Daniel D.
Farach-Carson Mary C.
French Margaret
Gomes Ronald
RatnerPrestia
Romeo David S
University of Delaware
LandOfFree
Delivery system for heparin-binding growth factors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery system for heparin-binding growth factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery system for heparin-binding growth factors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663660